Bioidentical hormones carry a lower risk of blood clots than older synthetic hormone formulations, but the risk isn’t zero. The type of hormone, how you take it, and your personal risk factors all play a significant role in whether hormone therapy raises your clot risk. The clearest finding from large studies: transdermal (through-the-skin) estradiol does not appear to increase clot risk at all, while oral estrogen of any kind does.
Why Estrogen Affects Blood Clotting
When you swallow an estrogen pill, it passes through your digestive tract and hits your liver before reaching the rest of your body. This “first pass” through the liver triggers changes in the proteins your blood uses to form clots. Specifically, oral estrogen increases levels of several clotting factors (including factors II, VII, VIII, and X, plus fibrinogen) while simultaneously lowering levels of natural anticoagulants that keep clotting in check. The net effect is blood that clots more easily than it should.
This matters because the clotting shift isn’t just theoretical. It translates into a real increase in venous thromboembolism, the medical term for blood clots that form in deep veins and can travel to the lungs. The risk is highest with potent synthetic estrogens like ethinyl estradiol (used in birth control pills) and conjugated equine estrogens (derived from horse urine, used in older menopause therapies).
How Bioidentical Estradiol Compares
Bioidentical estradiol is chemically identical to the estrogen your ovaries produce. Comprehensive safety reviews have found that bioidentical estrogens are associated with a reduced risk of blood clots compared to non-bioidentical preparations. But the delivery method matters enormously, sometimes more than the type of estrogen itself.
The ESTHER study, one of the most cited investigations on this topic, found that oral estrogen use was associated with a 4.5-fold increase in clot risk compared to nonusers. Transdermal estradiol, by contrast, showed an odds ratio of just 1.1, meaning it carried essentially no additional risk. A separate prospective study confirmed the mechanism: oral hormone therapy led to rapid, elevated production of thrombin (a key clotting protein), while transdermal estradiol produced thrombin levels similar to those seen in women not using hormones at all.
The reason is straightforward. Patches, gels, and sprays deliver estradiol directly into your bloodstream through the skin, bypassing the liver entirely. Without that first-pass liver effect, the coagulation cascade stays largely undisturbed. Studies measuring a specific marker called activated protein C resistance (which predisposes to clotting) found that oral estradiol consistently increased it, while transdermal estradiol had little or no effect.
Progesterone vs. Synthetic Progestins
If you have a uterus and take estrogen, you also need a progestogen to protect the uterine lining. Here, too, the bioidentical option appears safer for clot risk. Micronized progesterone, the bioidentical form, has been studied in systematic reviews looking specifically at cardiovascular and clotting events. The findings: combining estrogen with micronized progesterone did not alter the risk of primary or recurrent blood clots, and it did not increase stroke risk either.
This stands in contrast to certain synthetic progestins, particularly norpregnane derivatives, which have been linked to increased clot risk when combined with estrogen. In placebo-controlled randomized trials, micronized progesterone showed no significant difference in clotting events compared to placebo groups.
Your Personal Risk Factors Matter
Even with the safest hormone formulation, your baseline clot risk shapes the overall picture. Three common factors interact in powerful ways: body weight, blood type, and a genetic mutation called Factor V Leiden.
A large case-control study of over 11,000 people found that being in the highest weight category (BMI above about 27) nearly doubled the risk of venous blood clots on its own. Having a non-O blood type (A, B, or AB) added further risk. Factor V Leiden, a clotting gene mutation carried by roughly 5% of people with European ancestry, compounded things further. When all three factors were present together, clot risk was 12.5 times higher than the reference group of lean individuals with type O blood and no genetic mutation.
The ESTHER study revealed an especially striking interaction between weight and oral estrogen. Women who were obese and took oral estrogen had a clot risk over 20 times higher than normal-weight nonusers. But women who were obese and used transdermal estradiol had roughly the same clot risk as obese women not using hormones at all. In other words, transdermal delivery eliminated the additional risk that oral estrogen would have added on top of their weight-related baseline risk.
What Medical Societies Recommend
The North American Menopause Society’s 2022 position statement emphasizes that hormone therapy risks vary by type, dose, duration, route of administration, and timing. For women under 60 or within 10 years of menopause who have no contraindications, the benefit-risk ratio is generally favorable for treating bothersome symptoms like hot flashes and for preventing bone loss. For women starting hormones more than 10 years after menopause or after age 60, the absolute risks of clots, stroke, and heart disease increase enough to shift that balance.
Some clinicians now prescribe transdermal estradiol specifically for women who have personal or family histories of blood clots. A case series of 115 women with prior clotting events who were given transdermal estradiol-based hormone therapy reflects this approach, supported by observational data showing that transdermal estradiol has a “neutral effect” on clot and stroke risk beyond whatever predisposition a woman already carries.
Compounded vs. FDA-Approved Bioidenticals
It’s worth distinguishing between FDA-approved bioidentical hormones and custom-compounded versions. FDA-approved products like estradiol patches, gels, and micronized progesterone capsules have been tested in the clinical trials described above. Compounded bioidentical hormones, mixed by specialty pharmacies in custom doses or combinations, use the same base molecules but lack standardized testing for consistency, absorption, and safety outcomes. The clot-risk data referenced here applies to the regulated, commercially manufactured versions. If you’re using compounded hormones, the same biological principles likely apply, but the evidence base is thinner and dosing is less predictable.
Reducing Your Risk in Practice
If minimizing clot risk is a priority, the evidence points to a few practical choices. Transdermal estradiol (patches, gels, or sprays) consistently shows a neutral effect on clotting, while oral estrogen of any kind raises risk. Micronized progesterone appears safer than synthetic progestins for the progestogen component. Starting hormone therapy closer to menopause rather than years later keeps the benefit-risk ratio more favorable.
Your individual risk profile also matters. If you carry excess weight, have a non-O blood type, or know you have Factor V Leiden, transdermal delivery becomes especially important because it avoids the compounding effect that oral estrogen adds to those existing risks. Some providers order clotting factor screening before prescribing hormone therapy, particularly if you have a personal or family history of blood clots.